KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Cash (2017 - 2025)

Aquestive Therapeutics has reported Change in Cash over the past 9 years, most recently at -$7.9 million for Q4 2025.

  • Quarterly results put Change in Cash at -$7.9 million for Q4 2025, down 24.37% from a year ago — trailing twelve months through Dec 2025 was $49.6 million (up 4.09% YoY), and the annual figure for FY2025 was $49.6 million, up 4.09%.
  • Change in Cash for Q4 2025 was -$7.9 million at Aquestive Therapeutics, down from $68.5 million in the prior quarter.
  • Over the last five years, Change in Cash for AQST hit a ceiling of $71.3 million in Q1 2024 and a floor of -$13.3 million in Q1 2022.
  • Median Change in Cash over the past 5 years was -$3.0 million (2021), compared with a mean of $4.5 million.
  • Peak annual rise in Change in Cash hit 18342.46% in 2024, while the deepest fall reached 582.75% in 2024.
  • Aquestive Therapeutics' Change in Cash stood at -$3.1 million in 2021, then skyrocketed by 374.65% to $8.6 million in 2022, then plummeted by 112.12% to -$1.0 million in 2023, then tumbled by 507.37% to -$6.3 million in 2024, then dropped by 24.37% to -$7.9 million in 2025.
  • The last three reported values for Change in Cash were -$7.9 million (Q4 2025), $68.5 million (Q3 2025), and -$8.1 million (Q2 2025) per Business Quant data.